Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants

Affiliations

¹ Department of Pharmacy, NewYork-Presbyterian Hospital Pharmacy, New York, New York, USA.
² Department of Surgery, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
³ Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
⁴ Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.

Free article

Nicholas W Lange et al. Am J Transplant. 2022 Jul.

Free article

. 2022 Jul;22(7):1925-1926.

doi: 10.1111/ajt.16955. Epub 2022 Jan 19.

¹ Department of Pharmacy, NewYork-Presbyterian Hospital Pharmacy, New York, New York, USA.
² Department of Surgery, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
³ Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
⁴ Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.

No abstract available

Comment in

Effect of nirmatrelvir/ritonavir on calcineurin inhibitor levels: Early experience in four SARS-CoV-2 infected kidney transplant recipients.
Wang AX, Koff A, Hao D, Tuznik NM, Huang Y. Wang AX, et al. Am J Transplant. 2022 Aug;22(8):2117-2119. doi: 10.1111/ajt.16997. Epub 2022 Feb 23. Am J Transplant. 2022. PMID: 35158412 Free PMC article. No abstract available.

1. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020;20(7):1800-1808.
1. Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for treatment of COVID-19. Science. 2021. doi: 10.1126/science.abl4784. Online ahead of print.
1. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371(25):2375-2382.
1. Badri P, Dutta S, Coakley E, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant. 2015;15(5):1313-1322.
1. Katezmaier S, Markert C, Riedel KD, Burhenne J, Hafeli WE, Mikus G. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther. 2011;90(5):666-673.